
Inhaler-delivered drug is a once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.


Inhaler-delivered drug is a once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.

New research suggests elderly patients with chronic obstructive pulmonary disease who participate in pulmonary rehabilitation programs have improved 10-year survival.

Study finds hyponatremia is an independent predictor of increased mortality, length of hospital stay, and postoperative complications in patients who undergo cardiac surgery.

The FDA has approved Daliresp to reduce the risk of COPD exacerbations in patients with severe COPD.
